Szulforafán irodalom

Sz.1.Anticancer Activity of a Broccoli Derivative, Sulforaphane, in Barrett Adenocarcinoma:

Potential Use in Chemoprevention and as Adjuvant in Chemotherapy

Aamer Qazi*,2, Jagannath Pal†,‡,2, Ma’in Maitah*,2,

Translational Oncology Volume 3 Number 6 December 2010 pp. 389399 389

Abstract

The incidence of Barrett esophageal adenocarcinoma (BEAC) has been increasing at an alarming rate in western countries. In this study, we have evaluated the therapeutic potential of sulforaphane (SFN), an antioxidant derived from broccoli, in BEAC. METHODS: BEAC cells were treated with SFN, alone or in combination with chemotherapeutic, paclitaxel, or telomerase-inhibiting agents (MST-312, GRN163L), and live cell number determined at various time points. The effect on drug resistance/chemosensitivity was evaluated by rhodamine efflux assay. Apoptosis was detected by annexin V labeling and Western blot analysis of poly(ADP-ribose) polymerase cleavage. Effects on genes implicated in cell cycle and apoptosis were determined by Western blot analyses. To evaluate the efficacy in vivo, BEAC cells were injected subcutaneously in severe combined immunodeficient

mice, and after the appearance of palpable tumors, mice were treated with SFN. RESULTS: SFN induced both time- and dose-dependent decline in cell survival, cell cycle arrest, and apoptosis. The treatment with SFN also suppressed the expression of multidrug resistance protein, reduced drug efflux, and increased anticancer activity of other antiproliferative agents including paclitaxel. A significant reduction in tumor volume was also observed by SFN in a subcutaneous tumor model of BEAC. Anticancer activity could be attributed to the induction of caspase 8 and p21 and down-regulation of hsp90, a molecular chaperon required for activity of several proliferation-associated proteins. CONCLUSIONS: These data indicate that a natural product with antioxidant

properties from broccoli has great potential to be used in chemoprevention and treatment of BEAC.

 

Sz.2.Medicinal Plants: Their Use in Anticancer Treatment

M. Greenwell and P.K.S.M. Rahman*

Int J Pharm Sci Res. 2015 October 1; 6(10): 4103–4112. doi:10.13040/IJPSR.0975-8232.6(10).4103-12.

 

 Abstract

Globally cancer is a disease which severely effects the human population. There is a constant demand for new therapies to treat and prevent this life-threatening disease. Scientific and research interest is drawing its attention towards naturally-derived compounds as they are considered to have less toxic side effects compared to current treatments such as chemotherapy. The Plant Kingdom produces naturally occurring secondary metabolites which are being investigated for their anticancer activities leading to the development of new clinical drugs. With the success of these compounds that have been developed into staple drugs for cancer treatment new technologies are emerging to develop the area further. New technologies include nanoparticles for nano-medicines which aim to enhance anticancer activities of plant-derived drugs by controlling the release of the compound and investigating new methods for administration. This review discusses the demand for naturally-derived compounds from medicinal plants and their properties which make them targets for potential anticancer treatments.

 

 

[1] Clarke JD, Dashwood RH, and Ho E (2008). Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269, 291–304.

[2] Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, and Shields PG (2004). Breast cancer risk in premenopausal women is inversely associated

with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr 134, 1134–1138.

[3] Joseph MA, Moysich KB, Freudenheim JL, Shields PG, Bowman ED, Zhang Y, Marshall JR, and Ambrosone CB (2004). Cruciferous vegetables, genetic polymorphisms

in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr Cancer 50, 206–213.

[4] van Poppel G, Verhoeven DT, Verhagen H, and Goldbohm RA (1999). Brassica vegetables and cancer prevention. Epidemiology and mechanisms. Adv Exp Med

Biol 472, 159–168.

[5] Chung FL, Conaway CC, Rao CV, and Reddy BS (2000). Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate.

Carcinogenesis 21, 2287–2291.

[6] Zhang Y, Talalay P, Cho CG, and Posner GH (1992). A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of

structure. Proc Natl Acad Sci USA 89, 2399–2403.

[7] Campas-Baypoli ON, Sanchez-Machado DI, Bueno-Solano C, Ramirez-Wong B, and Lopez-Cervantes J (2010). HPLC method validation for measurement of

sulforaphane level in broccoli by-products. Biomed Chromatogr 24, 387–392.

[8] Fahey JW, Zhang Y, and Talalay P (1997). Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens.

Proc Natl Acad Sci USA 94, 10367–10372.

[9] Zhang Yand Talalay P (1994). Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res 54, 1976s–1981s.

[10] Singh SV, Herman-Antosiewicz A, Singh AV, Lew KL, Srivastava SK, Kamath R, Brown KD, Zhang L, and Baskaran R (2004). Sulforaphane-induced G2/M phase

cell cycle arrest involves checkpoint kinase 2–mediated phosphorylation of cell division cycle 25C. J Biol Chem 279, 25813–25822.

[11] Hu R, Khor TO, Shen G, Jeong WS, Hebbar V, Chen C, Xu C, Reddy B, Chada K, and Kong AN (2006). Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 27, 2038–2046.

[12] Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, and Conaway CC (2002). Sulforaphane and its metabolite mediate growth arrest and apoptosis in

human prostate cancer cells. Int J Oncol 20, 631–636.

[13] Wang L, Liu D, Ahmed T, Chung FL, Conaway C, and Chiao JW (2004). Targeting cell cycle machinery as a molecular mechanism of sulforaphane in

prostate cancer prevention. Int J Oncol 24, 187–192.

[14] Pappa G, Lichtenberg M, Iori R, Barillari J, Bartsch H, and Gerhauser C (2006). Comparison of growth inhibition profiles and mechanisms of apoptosis

induction in human colon cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat Res 599, 76–87.

[15] Cho SD, Li G, Hu H, Jiang C, Kang KS, Lee YS, Kim SH, and Lu J (2005). Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated

apoptosis induced by sulforaphane in DU145 prostate cancer cells. Nutr Cancer 52, 213–224.

[16] Gamet-Payrastre L, Li P, Lumeau S, Cassar G,DupontMA, Chevolleau S, Gasc N, Tulliez J, and Tercé F (2000). Sulforaphane, a naturally occurring isothiocyanate,

induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60, 1426–1433.

[17] Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, and Hedley DW (2004). The dietary isothiocyanate sulforaphane targets pathways of apoptosis,

cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther 3, 1239–1248.

[18] Singh AV, Xiao D, Lew KL, Dhir R, and Singh SV (2004). Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and

retards growth of PC-3 xenografts in vivo. Carcinogenesis 25, 83–90.

[19] MatsuiTA,MurataH, SakabeT, Sowa Y,HorieN,Nakanishi R, SakaiT, and KuboT (2007). Sulforaphane induces cell cycle arrest and apoptosis in murine osteosarcoma

cells in vitro and inhibits tumor growth in vivo. Oncol Rep 18, 1263–1268.

[20] Dinkova-Kostova AT, Jenkins SN, Fahey JW, Ye L, Wehage SL, Liby KT, Stephenson KK, Wade KL, and Talalay P (2006). Protection against UV-light–

induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Lett 240, 243–252.

[21] Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, Conney AH, and Kong AN (2006). Inhibition of 7,12-dimethylbenz(a)anthracene–induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2–related factor 2. Cancer Res 66, 8293–8296.

[22] Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, and Lozniewski A (2002). Sulforaphane inhibits extracellular, intracellular,

and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA 99, 7610–7615.

[23] Thejass P and Kuttan G (2006). Augmentation of natural killer cell and antibodydependent cellular cytotoxicity in BALB/c mice by sulforaphane, a naturally occurring

isothiocyanate from broccoli through enhanced production of cytokines IL-2 and IFN-gamma. Immunopharmacol Immunotoxicol 28, 443–457.

[24] Thejass P and Kuttan G (2007). Modulation of cell-mediated immune response in B16F-10 melanoma-induced metastatic tumor-bearing C57BL/6 mice by

sulforaphane. Immunopharmacol Immunotoxicol 29, 173–186.

[25] Blot WJ and McLaughlin JK (1999). The changing epidemiology of esophageal cancer. Semin Oncol 26, 2–8.

[26] Devesa SS, Blot WJ, and Fraumeni JF Jr (1998). Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83, 2049–2053.

[27] Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtulla A, and Beer DG (2000). Indomethacin-induced apoptosis in esophageal adenocarcinoma cells

involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia 2, 346–356.

[28] Ogunwobi OO and Beales IL (2008). Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol 103, 825–837.

 [29] Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, Harper E, Harrison R, Attwood SE, and Jankowski JA (2003). Upregulation of the oncogene

c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52, 174–180.

[30] Yoshida N, Katada K, Handa O, Takagi T, Kokura S, Naito Y, Mukaida N, Soma T, Shimada Y, Yoshikawa T, et al. (2007). Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Mol Med 19, 335–340.

[31] Andelova H, Rudolf E, and Cervinka M (2007). In vitro antiproliferative effectsof sulforaphane on human colon cancer cell line SW620. Acta Medica (Hradec

Kralove) 50, 171–176.

[32] Chuang LT, Moqattash ST, Gretz HF, Nezhat F, Rahaman J, and Chiao JW (2007). Sulforaphane induces growth arrest and apoptosis in human ovarian

cancer cells. Acta Obstet Gynecol Scand, 1–6.

[33] Jin CY, Moon DO, Lee JD, Heo MS, Choi YH, Lee CM, Park YM, and Kim GY (2007). Sulforaphane sensitizes tumor necrosis factor–related apoptosisinducing ligand-mediated apoptosis through downregulation of ERK and Aktin lung adenocarcinoma A549 cells. Carcinogenesis 28, 1058–1066.

[34] Mi L, Wang X, Govind S, Hood BL, Veenstra TD, Conrads TP, Saha DT, Goldman R, and Chung FL (2007). The role of protein binding in induction

of apoptosis by phenethyl isothiocyanate and sulforaphane in human non–small lung cancer cells. Cancer Res 67, 6409–6416.

[35] Park SY, Kim GY, Bae SJ, Yoo YH, and Choi YH (2007). Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma

HepG2 cells through activation of caspase-3. Oncol Rep 18, 181–187.

[36] Shan Y, Sun C, Zhao X, Wu K, Cassidy A, and Bao Y (2006). Effect of sulforaphane on cell growth, G(0)/G(1) phase cell progression and apoptosis in human bladder cancer T24 cells. Int J Oncol 29, 883–888.

[37] Chaudhuri D, Orsulic S, and Ashok BT (2007). Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol Cancer Ther 6, 334–345.

[38] Pledgie-Tracy A, SobolewskiMD, and Davidson NE (2007). Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines. Mol Cancer Ther 6,

1013–1021.

[39] Yeh CTand Yen GC (2005). Effect of sulforaphane on metallothionein expressionand induction of apoptosis in human hepatoma HepG2 cells. Carcinogenesis 26,

2138–2148.

[40] Vanhoefer U, Cao S,Minderman H, Tóth K, Scheper RJ, Slovak ML, and Rustum YM (1996). PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin

resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 2, 369–377.

[41] Mi L, Xiao Z, Hood BL, Dakshanamurthy S, Wang X, Govind S, Conrads TP, Veenstra TD, and Chung FL (2008). Covalent binding to tubulin by isothiocyanates:

a mechanism of cell growth arrest and apoptosis. J Biol Chem 283,

22136–22146.

[42] Myzak MC, Hardin K, Wang R, Dashwood RH, and Ho E (2006). Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate

epithelial cells. Carcinogenesis 27, 811–819.

[43] Herman-Antosiewicz A, Xiao H, Lew KL, and Singh SV (2007). Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP humanprostate cancer cell line. Mol Cancer Ther 6, 1673–1681.

[44] Shen G, Xu C, Chen C, Hebbar V, and Kong AN (2006). p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated

with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol 57, 317–327.

[45] Myzak MC, Karplus PA, Chung FL, and Dashwood RH (2004). A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.Cancer Res 64, 5767–5774.

[46] Jeong WS, Kim IW, Hu R, and Kong AN (2004). Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line.Pharm Res 21, 649–660.

[47] Jakubikova J, Sedlak J, Mithen R, and Bao Y (2005). Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 69, 1543–1552.

[48] Xu C, Shen G, Chen C, Gelinas C, and Kong AN (2005). Suppression of NF- κB and NF-κB–regulated gene expression by sulforaphane and PEITC through IκBα, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24, 4486–4495